View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
August 19, 2012

TG Therapeutics, Rhizen partner to develop cancer drug

TG Therapeutics and Rhizen Pharmaceuticals have partnered to develop and commercialise Rhizen's PI3K delta inhibitor, TGR-1202, previously known as RP5264.

TG Therapeutics and Rhizen Pharmaceuticals have partnered to develop and commercialise Rhizen’s PI3K delta inhibitor, TGR-1202, previously known as RP5264.

Under the collaboration, which will initially focus on hematologic malignancies and autoimmune disease indications, the companies will jointly develop the product on a worldwide basis, excluding India.

Rhizen will contribute backup molecules, enabling TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.

TG Therapeutics executive chairman and interim CEO Michael S Weiss said the company has entered into collaboration with Rhizen due to their innovative pre-clinical development program, which has yielded an impressive portfolio of PI3K delta inhibitors.

"TGR-1202 has already demonstrated encouraging pre-clinical activity, and will serve to expand our pipeline as we seek to develop much needed therapies for patients suffering from hematologic malignancies," Weiss said.

Under the agreement, TG will cover the costs of clinical development up to Phase II, after which the companies will be jointly responsible.

Rhizen is eligible to receive upfront, development, and commercialisation milestone payments in addition to royalties tied to net sales, the aggregate of which is expected to exceed $250m.

Rhizen president Swaroop Vakkalanka said; "The deep clinical and regulatory development knowledge and experience of the team at TG Therapeutics, and the existing clinical program focused on B-cell malignancies, makes TG an ideal partner with which to collaborate on development of TGR-1202."

Rhizen will maintain rights to manufacture and supply the product to TG Therapeutics, which will be responsible for all clinical and regulatory development for TGR-1202.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena